drugset / Trial / NCT07857135
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is a multi-center, open-label, dose-escalation, dose-expansion, and cohort-expansion first-in-human Phase 1/2 study to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor efficacy of SYS6088 in patients with advanced/metastatic solid tumors.
Timeline
- Start
- 2026-10-03
- Primary completion
- 2029-02-03
- Completion
- 2029-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ivonescimab | Monoclonal antibody | — | — |
| Comparator | Regorafenib | Small molecule | — | — |
| Subject | SYS6088 | Unknown | — | — |
Indications
No indication recorded.